Close this search box.

Regeneron adds to ovarian cancer target innovation at ESMO

ARTICLE | Product Development

Regeneron data show signs of activity with a new ovarian tumor target, and solidify company’s PD-1 position in skin cancer

By Lauren Martz, Executive Director, Biopharma Intelligence

October 26, 2023 1:12 AM UTC

Innovation in ovarian cancer targets was an emerging theme running through early-stage data presented at the ESMO 2023 Congress, and Regeneron was among the small but notable set of companies presenting data on a new tumor antigen for the challenging indication.

At the meeting, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) presented data from a Phase I dose-escalation study of ubamatamab (REGN4018), a MUC16 x CD3 bispecific in development to treat recurrent ovarian cancer…